Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 16/20 | 0.46 |
| ▸ | FEN1 | P39748 | 15/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.45 |
| ▸ | BAD | Q92934 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6167248 | 0.87 | PTGS1 (0.47) | ALOX5APFEN1 | |
| SCHEMBL6162420 | 0.85 | RXRA (0.43) | ALOX5APFEN1MAP4K4RXRARXRB | |
| SCHEMBL7107058 | 0.82 | ALOX5AP (0.52) | ALOX5APFEN1 | |
| SCHEMBL890690 | 0.81 | ALOX5AP (0.54) | ALOX5APFEN1 | |
| SCHEMBL21962266 | 0.77 | PTK2B (0.48) | — | |
| SCHEMBL26144894 | 0.75 | PTK2B (0.62) | — | |
| SCHEMBL6166229 | 0.73 | HPGD (0.48) | — | |
| SCHEMBL24429412 | 0.72 | CCR2 (0.50) | ALOX5APFEN1 | |
| SCHEMBL3716571 | 0.72 | ALDH1A1 (0.54) | — | |
| SCHEMBL411705 | 0.72 | BCL2L1 (0.62) | FEN1BCL2L1BADMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254136-A4 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD (KR) | 2005-06-01 | — | — | EP | disclosed |
| US-20030065176-A1 | Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof | LG CHEM INVESTMENT LTD. (KR) | 2003-04-03 | — | — | US | disclosed |
| EP-1254136-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG Chem Investment, Ltd. (KR) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001055146-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD. (KR) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065176-A1 | Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof | F2, F12, TFPI | ALOX5AP 680/4885FEN1 2108/4885BCL2L1 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.